Premium
Pharmacology of ADP ‐ribosylation
Author(s) -
Schüler Herwig,
Ziegler Mathias
Publication year - 2013
Publication title -
the febs journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 204
eISSN - 1742-4658
pISSN - 1742-464X
DOI - 10.1111/febs.12388
Subject(s) - parp1 , adp ribosylation , pharmacology , drug , drug development , poly adp ribose polymerase , enzyme , cancer , biology , biochemistry , nad+ kinase , genetics , polymerase
ADP‐ribosyltransferase ARTD1/PARP1 is a target for cancer and ischemia drug development. Several other ARTD‐family enzymes have been characterized in recent years, and it has become clear that their inhibition might also have therapeutic value. This minireview series summarizes current knowledge of pharmacological inhibition of ADP‐ribosyltransferases by a compound class called PARP inhibitors and the prospects for drug development.